Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults.

Department of Nutrition, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA.
Diabetologia (Impact Factor: 6.88). 08/2011; 55(1):63-72. DOI: 10.1007/s00125-011-2268-4
Source: PubMed

ABSTRACT The results of several studies have suggested a potential positive association between use of antidepressant medication (ADM) and incident type 2 diabetes mellitus. We examined this association in three cohorts of US adults.
We followed 29,776 men in the Health Professionals Follow-up Study (HPFS, 1990-2006), 61,791 women in the Nurses' Health Study I (NHS I, 1996-2008) and 76,868 women in NHS II (1993-2005), who were free of diabetes mellitus, cardiovascular disease or cancer at baseline. The mean baseline ages for participants from the HPFS and NHS I and II were 56.4, 61.3 and 38.1 years, respectively. ADM use and other covariates were assessed at baseline and updated every 2 years. A time-dependent Cox proportional hazards model was used, and HRs were pooled together across the three cohorts.
During 1,644,679 person-years of follow-up, we documented 6,641 new cases of type 2 diabetes. ADM use was associated with an increased risk of diabetes in all three cohorts in age-adjusted models (pooled HR 1.68 [95% CI 1.27, 2.23]). The association was attenuated after adjustment for diabetes risk factors and histories of high cholesterol and hypertension (1.30 [1.14, 1.49]), and further attenuated by controlling for updated BMI (1.17 [1.09, 1.25]). Use of selective serotonin reuptake inhibitors and other antidepressants (mainly tricyclic antidepressants) were both associated with an elevated risk of diabetes, with pooled multivariate-adjusted HRs of 1.10 (1.00, 1.22) and 1.26 (1.11, 1.42), respectively.
The results suggest that ADM users had a moderately elevated risk of type 2 diabetes mellitus compared with non-users, even after adjustment for BMI.

Download full-text


Available from: Michel Lucas, Jun 20, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Brassica juncea is a polyphenols enriched edible plant, with diverse medicinal uses of different parts of which have been mentioned in the Ayurveda. The effects of 10 daily oral doses (100, 200, and 400 mg/kg/day) of a methanolic Brassica juncea leaf extract in rat models of anxiety using nondiabetic and alloxan-diabetic rats were quantified. In all the three behavioural tests used, i.e. elevated plus maze, open field, and social interaction tests, anxiolytic-like activity of the extract was observed in the diabetic animals only. Quantitatively, the efficacy of the highest tested dose of the extract in these tests was always less than those observed after its lower ones. These observations provide further experimental evidences for the conviction that Brassica vegetables could as well be useful for combating diabetes associated mental health problems.
    02/2013; 3:7.1-7.7. DOI:10.5667/tang.2012.0042
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Bipolar I disorder (BPD) patients are often overweight or obese, and likely to have metabolic syndrome. Several medications used to treat BPD are associated with increased body weight and/or worsening metabolic parameters. METHODS: Metabolic data were analyzed from two efficacy studies of aripiprazole plus the mood stabilizers, lithium/valproate (Study CN138-189), or lamotrigine (Study CN138-392), in the long-term treatment (52 weeks) of BPD. Changes in body weight, individual metabolic parameters, and incidence of metabolic syndrome were assessed. RESULTS: In the lithium/valproate study, modest increases in body weight were observed at Week 52 in both groups: 1.7±0.8kg in the lithium/valproate group, and 1.6±0.7kg in the adjunctive aripiprazole group; this difference was nonsignificant. In the lamotrigine study, decreases in body weight were observed at Week 52 with lamotrigine alone (-2.2±1.0kg), whereas a modest increase was observed when combined with aripiprazole (0.4±1.0kg). In both studies, rates of metabolic syndrome at 52 weeks did not increase from baseline with aripiprazole, and median changes from baseline in individual metabolic syndrome parameters were similar with both mood stabilizer monotherapy and the addition of aripiprazole as an adjunctive therapy. LIMITATIONS: This was a post-hoc analysis, and a low percentage of patients completed the lamotrigine study. CONCLUSIONS: Aripiprazole plus a mood stabilizer has minimal impact on metabolic changes in predominantly overweight/obese BPD patients over a 52-week period. In both studies, modest mean increases in weight with the addition of aripiprazole were not accompanied by increased rates of metabolic syndrome or changes in metabolic parameters.
    Journal of Affective Disorders 12/2012; 148(1). DOI:10.1016/j.jad.2012.11.054 · 3.71 Impact Factor